{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:34:48Z","timestamp":1791178488726,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1038\/leu.2010.188","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T09:43:13Z","timestamp":1283420593000},"page":"1962-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1"],"prefix":"10.1038","volume":"24","author":[{"given":"D L","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"BFleu2010188_CR1","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064.","journal-title":"Blood"},{"key":"BFleu2010188_CR2","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761\u20132767.","journal-title":"J Clin Oncol"},{"key":"BFleu2010188_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"BFleu2010188_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/leu.2010.86","volume":"24","author":"A Bazeos","year":"2010","unstructured":"Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010; 24: 1243\u20131245.","journal-title":"Leukemia"},{"key":"BFleu2010188_CR5","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1073\/pnas.0730858100","volume":"100","author":"Y Shu","year":"2003","unstructured":"Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2010188_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00008571-200211000-00002","volume":"12","author":"R Kerb","year":"2002","unstructured":"Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12: 591.","journal-title":"Pharmacogenetics"},{"key":"BFleu2010188_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/tpj.2009.15","volume":"9","author":"ML Becker","year":"2009","unstructured":"Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9: 242.","journal-title":"Pharmacogenomics J"},{"key":"BFleu2010188_CR8","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750.","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010188","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:25:20Z","timestamp":1648733120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,2]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["BFleu2010188"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.188","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,2]]},"assertion":[{"value":"2 September 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}